CTMX Quote, Financials, Valuation and Earnings

Spero Therapeutics has a net margin of 49.55% compared to CytomX Therapeutics's net margin of -219.3%. CytomX Therapeutics's return on equity of -- beat Spero Therapeutics's return on equity of 4.36%.

CytomX Therapeutics has a consensus price target of $4.94, signalling upside risk potential of 680.14%. On the other hand Spero Therapeutics has an analysts' consensus of $5.00 which suggests that it could grow by 548.59%. Given that CytomX Therapeutics has higher upside potential than Spero Therapeutics, analysts believe CytomX Therapeutics is more attractive than Spero Therapeutics.

CytomX Therapeutics has a beta of 1.045, which suggesting that the stock is 4.544% more volatile than S&P 500. In comparison Spero Therapeutics has a beta of 0.685, suggesting its less volatile than the S&P 500 by 31.497%.

CytomX Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spero Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytomX Therapeutics pays -- of its earnings as a dividend. Spero Therapeutics pays out -- of its earnings as a dividend.

CytomX Therapeutics quarterly revenues are $38.1M, which are larger than Spero Therapeutics quarterly revenues of $7.8M. CytomX Therapeutics's net income of $18.9M is higher than Spero Therapeutics's net income of -$17.1M. Notably, CytomX Therapeutics's price-to-earnings ratio is 1.62x while Spero Therapeutics's PE ratio is 9.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytomX Therapeutics is 0.39x versus 0.46x for Spero Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals has a net margin of 49.55% compared to CytomX Therapeutics's net margin of -9.24%. CytomX Therapeutics's return on equity of -- beat Vanda Pharmaceuticals's return on equity of -3.49%.

CytomX Therapeutics has a consensus price target of $4.94, signalling upside risk potential of 680.14%. On the other hand Vanda Pharmaceuticals has an analysts' consensus of $12.67 which suggests that it could grow by 149.34%. Given that CytomX Therapeutics has higher upside potential than Vanda Pharmaceuticals, analysts believe CytomX Therapeutics is more attractive than Vanda Pharmaceuticals.

CytomX Therapeutics has a beta of 1.045, which suggesting that the stock is 4.544% more volatile than S&P 500. In comparison Vanda Pharmaceuticals has a beta of 0.689, suggesting its less volatile than the S&P 500 by 31.079%.

CytomX Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytomX Therapeutics pays -- of its earnings as a dividend. Vanda Pharmaceuticals pays out -- of its earnings as a dividend.

CytomX Therapeutics quarterly revenues are $38.1M, which are smaller than Vanda Pharmaceuticals quarterly revenues of $53.2M. CytomX Therapeutics's net income of $18.9M is higher than Vanda Pharmaceuticals's net income of -$4.9M. Notably, CytomX Therapeutics's price-to-earnings ratio is 1.62x while Vanda Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytomX Therapeutics is 0.39x versus 1.49x for Vanda Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of 49.55% compared to CytomX Therapeutics's net margin of 31.35%. CytomX Therapeutics's return on equity of -- beat Vertex Pharmaceuticals's return on equity of -3.23%.

CytomX Therapeutics has a consensus price target of $4.94, signalling upside risk potential of 680.14%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $496.78 which suggests that it could fall by -3.31%. Given that CytomX Therapeutics has higher upside potential than Vertex Pharmaceuticals, analysts believe CytomX Therapeutics is more attractive than Vertex Pharmaceuticals.

CytomX Therapeutics has a beta of 1.045, which suggesting that the stock is 4.544% more volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.629%.

CytomX Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytomX Therapeutics pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

CytomX Therapeutics quarterly revenues are $38.1M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.9B. CytomX Therapeutics's net income of $18.9M is lower than Vertex Pharmaceuticals's net income of $913M. Notably, CytomX Therapeutics's price-to-earnings ratio is 1.62x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytomX Therapeutics is 0.39x versus 12.09x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Verastem has a net margin of 49.55% compared to CytomX Therapeutics's net margin of -82.56%. CytomX Therapeutics's return on equity of -- beat Verastem's return on equity of -120.71%.

CytomX Therapeutics has a consensus price target of $4.94, signalling upside risk potential of 680.14%. On the other hand Verastem has an analysts' consensus of $12.57 which suggests that it could grow by 73.88%. Given that CytomX Therapeutics has higher upside potential than Verastem, analysts believe CytomX Therapeutics is more attractive than Verastem.

CytomX Therapeutics has a beta of 1.045, which suggesting that the stock is 4.544% more volatile than S&P 500. In comparison Verastem has a beta of 0.605, suggesting its less volatile than the S&P 500 by 39.46%.

CytomX Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verastem offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytomX Therapeutics pays -- of its earnings as a dividend. Verastem pays out -- of its earnings as a dividend.

CytomX Therapeutics quarterly revenues are $38.1M, which are larger than Verastem quarterly revenues of $10M. CytomX Therapeutics's net income of $18.9M is higher than Verastem's net income of -$24M. Notably, CytomX Therapeutics's price-to-earnings ratio is 1.62x while Verastem's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytomX Therapeutics is 0.39x versus -- for Verastem. Usually stocks with elevated PS ratios are considered overvalued.